Co-Diagnostics, Inc. (CODX)
OTCMKTS · Delayed Price · Currency is USD
2.830
-0.090 (-3.08%)
At close: Jan 16, 2026
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $145.38K in the quarter ending September 30, 2025, a decrease of -77.32%. This brings the company's revenue in the last twelve months to $507.89K, down -93.06% year-over-year. In the year 2024, Co-Diagnostics had annual revenue of $3.92M, down -42.53%.
Revenue (ttm)
507.89K
Revenue Growth
-93.06%
P/S Ratio
11.31
Revenue / Employee
3.85K
Employees
132
Market Cap
5.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
| Dec 31, 2019 | 214.97K | 175.06K | 438.63% |
| Dec 31, 2018 | 39.91K | 32.25K | 420.90% |
| Dec 31, 2017 | 7.66K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 10.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
Co-Diagnostics News
- 7 days ago - Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships - PRNewsWire
- 20 days ago - Co-Diagnostics announces 1-for-30 reverse stock split - Seeking Alpha
- 20 days ago - Co-Diagnostics Announces Reverse Stock Split - PRNewsWire
- 21 days ago - Co-Diagnostics (CODX) Secures Australian Patent for PCR Platform - GuruFocus
- 21 days ago - Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies - PRNewsWire
- 4 weeks ago - Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India - PRNewsWire
- 4 weeks ago - Co-Diagnostics (CODX) Validates Efficacy of Influenza and COVID-19 Detection Test - GuruFocus
- 4 weeks ago - Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation - PRNewsWire